Información de la revista
Vol. 61. Núm. 2.
Páginas 131-136 (agosto 2004)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 61. Núm. 2.
Páginas 131-136 (agosto 2004)
Acceso a texto completo
Enfermedad de Graves: estado actual y revisión de 20 casos
Graves' disease in children: management and review of 20 patients
Visitas
10910
O. Rubio Cabezas
Autor para correspondencia
prucab@terra.es

Correspondencia: Servicio de Endocrinología. Hospital Infantil Universitario Niño Jesús. Avda. Menéndez Pelayo, 65. 28009 Madrid. España
, M.aT. Muñoz Calvo, J. Pozo Román, J. Argente Oliver
Servicio de Endocrinología. Hospital Infantil Universitario Niño Jesús. Madrid. España
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Introducción

El hipertiroidismo es poco frecuente en la infancia y aparece, en general, en el contexto de la enfermedad de Graves. La mejor forma de tratamiento continúa siendo objeto de debate

Pacientes y métodos

Se han revisado de forma retrospectiva las historias clínicas de 20 pacientes diagnosticados de enfermedad de Graves entre 1989 y 2003. Se ha analizado la sintomatología clínica inicial, la función tiroidea, los marcadores de autoinmunidad tiroidea, las pruebas de imagen tiroideas, el tratamiento de primera elección, las complicaciones de la enfermedad o del tratamiento, la necesidad de recurrir a tratamientos alternativos, así como su efecto sobre el paciente

Resultados

La edad en el momento del diagnóstico osciló entre 5 y 16 años, con un predominio del sexo femenino (3:1). El síntoma más frecuente fue el nerviosismo (58 %). El signo más frecuente fue el bocio (79 %). El 90 % de los pacientes presentaron anticuerpos estimuladores del tiroides (TSI) al inicio de la enfermedad o durante la evolución. Todos los pacientes fueron inicialmente tratados con fármacos antitiroideos, pero la remisión de la enfermedad sólo se logró en 1 caso. En 3 casos hubo que recurrir a la tiroidectomía por falta de respuesta o aparición de complicaciones, y dos más recibieron radioyodo

Conclusión

Dado que la remisión de la enfermedad de Graves con el tratamiento médico es poco habitual, con frecuencia hay que recurrir a otro tipo de terapia (cirugía o radioyodo). Aunque los fármacos antitiroideos continúan siendo la primera opción terapéutica en nuestro medio, algunos autores abogan por el radioyodo como tratamiento de elección

Palabras clave:
Enfermedad de Graves
Hipertiroidismo
Introduction

Hyperthyroidism is a rare condition among children and the most common cause is Graves' disease. The best therapy for these patients continues to be debated

Patients and methods

The medical records of 20 patients with Graves' hyperthyroidism who were treated between 1989 and 2003 were reviewed. Clinical symptoms, thyroid function, thyroid autoantibodies, thyroid imaging tests, first line therapy, disease or treatment-induced complications and the need for a secondary treatment option, as well as outcomes, were analyzed

Results

Age at diagnosis ranged from 5 to 16 years and there were more girls than boys (3:1). The most frequent symptom was hyperactivity (58 %). The most frequent sign was goiter (79 %). Thyroid-stimulating immunoglobulin antibodies were found in 90 % of the patients, at the beginning or during the course of the disease. All of the patients received antithyroid medication as first line therapy, but remission was achieved in just one patient. Surgical thyroidectomy was required in three patients, and two patients were treated with radioiodine

Conclusion

Because few children achieve remission with medical therapy, other types of treatment (surgery or radioiodine) are often required. Although antithyroid drugs are considered the first choice for treatment in Europe, some authors advocate radioiodine as the treatment of choice

Key words:
Graves
Hyperthyroidism
El Texto completo está disponible en PDF
Bibliografía
[1.]
A. Weetman.
graves' disease.
N Engl J Med, 343 (2000), pp. 1236-1248
[2.]
J. Ginsberg.
Diagnosis and management of graves' disease.
Cmaj, 168 (2003), pp. 575-585
[3.]
Z. Kraeim, R.S. Newfield.
graves' disease in childhood.
J Pediatr Endocrinol Metab, 14 (2001), pp. 229-243
[4.]
M.H. Mokhashi, U. Desai, M.P. Desai.
Hyperthyroidism in children.
Indian J Pediatr, 67 (2000), pp. 653-656
[5.]
D. Zimmerman, A.N. Lteif.
Thyrotoxicosis in children.
Endocrinol Metab Clin North Am, 27 (1998), pp. 109-126
[6.]
M. Polak.
Hyperthyroidism in early infancy: Pathogenesis, clinical features and diagnosis with a focus on neonatal hyperthyroidism.
Thyroid, 8 (1998), pp. 1171-1177
[7.]
M. Segni, E. Leonardi, B. Mazzoncini, I. Pucarelli, A.M. Pasquino.
Special features of graves' disease in early childhood.
Thyroid, 9 (1999), pp. 871-877
[8.]
L. Lazar, O. Kalter-Leibovici, A. Pertzelan, N. Weintrob, Z. Josefsberg, M. Phillip.
Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients.
J Clin Endocrinol Metab, 85 (2000), pp. 3678-3682
[9.]
C.A. Koch, N.J. Sarlis.
The spectrum of thyroid diseases in childhood and its evolution during transition to adulthood: Natural history, diagnosis, differential diagnosis and management.
J Endocrinol Invest, 24 (2001), pp. 659-675
[10.]
J. Dotsch, W. Rascher, H.G. Dorr.
graves' disease in childhood: A review of the options for diagnosis and treatment.
Paeditr Drugs, 5 (2003), pp. 95-102
[11.]
J.H. Waldhausen.
Controversies related to the medical and surgical management of hyperthyroidism in children.
Semin Pediatr Surg, 6 (1997), pp. 121-127
[12.]
H. Perrild, L. Lavard, B. Brock-Jacobsen.
Clinical aspects and treatment of juvenile graves' disease.
Exp Clin Endocrinol Diabetes, 105 (1997), pp. 55-57
[13.]
T.D. Cheetham, I.A. Hughes, N.D. Barnes, E.P. Wraight.
Treatment of hyperthyroidism in young people.
Arch Dis Child, 78 (1998), pp. 207-209
[14.]
A. Grüters.
Treatment of graves' disease in chidren and adolescents.
Horm Res, 49 (1998), pp. 255-257
[15.]
S.A. Rivkees, C. Sklar, M. Freemark.
The management of graves' disease in children, with special enphasis on radioiodine treatment.
J Clin Endocrinol Metab, 83 (1998), pp. 3767-3776
[16.]
A. Allahabadia, J. Daykin, R.L. Holder, M.C. Sheppard, S.C. Gough, J.A. Franklyn.
Age and gender predict the outcome of treatment for graves' hyperthyroidism.
J Clin Endocrinol Metab, 85 (2000), pp. 1038-1042
[17.]
N.S. Glaser, D.M. Styne.
Predictors of early remission of hyperthyroidism in children.
J Clin Endocrinol Metab, 82 (1997), pp. 1719-1726
[18.]
B.M. Lippe, E.M. Landaw, S.A. Kaplan.
Hyperthyroidism in children treated with long term medical therapy: Twenty-five percent remission every two years.
J Clin Endocrinol Metab, 64 (1987), pp. 1241-1245
[19.]
G.C. Mussa, A. Corrias, L. Silvestro, E. Battan, M. Mostert, F. Mussa, et al.
Factors at onset predictive of lasting remission in pediatric patients with graves' disease followed for at least three years.
J Pediatr Endocrinol Metab, 12 (1999), pp. 537-541
[20.]
D.I. Shulman, I. Muhar, F.V. Jorgesen, F.B. Diamond, B.B. Bercu, A.W. Root.
Autoimmune hyperthyroidism in prepubertal children and adolescents: Comparison of clinical and biochemical features at diagnosis and responses to medical therapy.
Thyroid, 7 (1997), pp. 755-760
[21.]
L. Ward, C. Hout, R. Lambert, C. Deal, R. Collu, G. Van Vliet.
Outcome of pediatric graves' disease after treatment with antithyroid medication and radioiodine.
Clin Invest Med, 22 (1999), pp. 132-139
[22.]
P. Bergman, A. Auldist, F. Cameron.
Review of the outcome of management of graves' disease in children and adolescents.
J Pediatr Child Health, 37 (2001), pp. 176-182
[23.]
M. Segni, C.A. Gorman.
The aftermath of childhood hyperthyroidism.
J Pediatr Endocrinol Metab, 14 (2001), pp. 1277-1282
[24.]
J. Witte, P.E. Goretzki, H.D. Roher.
Surgery for graves disease in childhood and adolescence.
Exp Clin Endocrinol Diabetes, 105 (1997), pp. 58-60
[25.]
T.K. Palit, C.C. Miller, D.M. Miltenburg.
The efficacy of thyroidectomy for graves' disease: A meta-analysis.
J Surg Res, 90 (2000), pp. 161-165
[26.]
T.D. Cheetham, E.P. Wraight, I.A. Hughes, N.D. Barnes.
Radioiodine treatment of graves' disease in young children.
Horm Res, 49 (1998), pp. 258-262
[27.]
S.A. Rivkees, E.A. Cornelius.
Influence of iodine-131 dose on the outcome of hyperthyroidism in children.
Pediatrics, 111 (2003), pp. 745-749
[28.]
M. Hernández, J. Castellet, J.L. Narvaíza, J.M. Rincón, E. Ruiz, E. Sánchez, et al.
Curvas y tablas de crecimiento. Instituto de Investigación sobre Crecimiento y Desarrollo.
Fundación Faustino Orbegozo,
[29.]
J.M. Tanner, R.H. Whitehouse.
Clinical longitudinal standards for height, weight, height velocity, weight velocity and stages of puberty.
Arch Dis Child, 51 (1976), pp. 170-179
[30.]
W.W. Greulich, S.I. Pyle.
Radiographic atlas of skeletal development of the hand and wrist, 2nd ed,
[31.]
F. Monaco.
Classification of thyroid diseases: Suggestions for a revision.
J Clin Endocrinol Metab, 88 (2003), pp. 1428-1432
[32.]
E.N. Pearce, A.P. Farwell, L.E. Braverman.
Thyroiditis.
N Engl J Med, 348 (2003), pp. 2646-2655
[33.]
C. Pavía Sesma, J. Villanueva Lamas, M. Torres Lacruz, C. Valls Tolosa, F. Rodríguez Hierro, M.R. Martín Ramos, et al.
Enfermedad de graves-Basedow en la infancia y la adolescencia: aspectos clinicobiológicos en 49 casos.
An Esp Pediatr, 53 (2000), pp. 6-11
[34.]
J. Raza, P.C. Hindmarsh, C.G.D. Brook.
Thyrotoxicosis in children: Thirty years' experience.
Acta Pediatr, 88 (1999), pp. 937-941
[35.]
W. Chan, G.W. Wong, D.S. Fan, A.C. Cheng, D.S. Lam, J.S. Ng.
Ophtalmopathy in childhood graves' disease.
Br J Ophthalmol, 86 (2002), pp. 740-742
[36.]
G.W.K. Wong, J. Lai, P.S. Cheng.
Growth in childhood thyrotoxicosis.
Eur J Pediatr, 158 (1999), pp. 776-779
[37.]
B. Vaidya, P. Kendall-Taylor, S.H.S. Pearce.
The genetics of autoimmune thyroid disease.
J Clin Endocrinol Metab, 87 (2002), pp. 5385-5397
[38.]
L. Soriano Guillén, M.T. Muñoz Calvo, J. Pozo Román, J. Martínez Pérez, A. Baño Rodrigo, J. Argente Oliver.
Enfermedad de graves en pacientes con síndrome de Down.
An Pediatr (Barc), 58 (2003), pp. 63-66
[39.]
K. Hashizume, K. Ichikawa, A. Sakurai, S. Suzuki, T. Takeda, M. Kobayashi, et al.
Administration of thyroxine in treated graves' disease; effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
N Engl J Med, 324 (1991), pp. 947-953
[40.]
B. McIver, P. Rae, G. Beckett, E. Wilkinson, A. Gold, E. Toft.
Lack of effect of thyroxine in patients with graves' hyperthyroidism who are treated with an antithyroid drug.
N Engl J Med, 334 (1996), pp. 220-224
[41.]
K. Hashizume, K. Ichikawa, A. Sakurai, S. Suzuki, T. Takeda, M. Kobayashi, et al.
Administration of thyroxine in treated graves disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
N Eng J Med, 324 (1991), pp. 947-953
[42.]
B. McIver, P. Rae, G. Beckett, E. Wilkinson, A. Fold, A. Toft.
Lack of effect of thyroxine in patients with graves' hyperthyroidism who are treated with an antithyroid drug.
N Engl J Med, 334 (1996), pp. 220-224
Copyright © 2004. Asociación Española de Pediatría
Descargar PDF
Idiomas
Anales de Pediatría
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?